3 Horrendous Health-Care Stocks This Week
Motley Fool
This Week in Biotech: Part 2
Motley Fool
What Orexigen Is Saying -- and Not Saying
Motley Fool
Vivus Weight-Loss Drug Launch In Early Trouble
TheStreet.com
Down 20%: What Is VIVUS' Market Opportunity?
Motley Fool
The Wild October Ride Of Vivus
Seeking Alpha

